Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
160 results
  • Targeting interleukin-1β and inflammation in lung cancer. [Review]
    Biomark Res. 2022 Jan 27; 10(1):5.Zhang J, Veeramachaneni N
  • Inflammation is a process that protects organs against various potentially harmful stimuli and enables repair. Dysregulated inflammation, however, damages tissues and leads to disease, including cancer. Cancer-related inflammation is characterized by cytokine production, leukocyte infiltration, angiogenesis, and tissue remodeling-all critical processes in modulating the tumor microenvironment (TM…
  • Engineering a Next-Gen IL2 Therapy. [Journal Article]
    Cancer Discov. 2021 Jun; 11(6):1312-1313.
  • The "immunocytokine" PD1-IL2v, a fusion of a PD-1 antibody and modified IL2, may circumvent some side effects of the decades-old recombinant IL2 therapy aldesleukin while also enhancing efficacy. Whether this strategy works in patients is now being put to the test in a clinical trial.
  • Humanized Mouse as a Tool to Predict Immunotoxicity of Human Biologics. [Journal Article]
    Front Immunol. 2020; 11:553362.Yong KSM, Her Z, … Chen Q
  • Advancements in science enable researchers to constantly innovate and create novel biologics. However, the use of non-human animal models during the development of biologics impedes identification of precise in vivo interactions between the human immune system and treatments. Due to lack of this understanding, adverse effects are frequently observed in healthy volunteers and patients exposed to p…
  • Systemic Therapies for Advanced Melanoma. [Review]
    Dermatol Clin. 2019 Oct; 37(4):409-423.Bomar L, Senithilnathan A, Ahn C
  • The incidence of metastatic melanoma continues to increase each decade. Although surgical treatment is often curative for localized stage I and stage II disease, the median survival for patients with distant metastases is less than 1 year. The last 2 decades have witnessed a breakthrough in therapeutic options with the development of immune checkpoint inhibitors, small molecule targeted therapy, …
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Aldesleukin [BOOK]
    LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Aldesleukin is a recombinant form of human interleukin-2, a cytokine that stimulates the proliferation and maturation of T cells, which is used in immune therapy of renal cell cancer and malignant melanoma. When given in high doses, interleukin-2 regularly causes mild-to-moderate elevations in serum enzymes and bilirubin, but it rarely results in clinically significant acute liver injury.
New Search Next